Breaking News, Collaborations & Alliances

Immetas, GC Biopharma Partner on mRNA Therapeutics to Treat Autoimmune Diseases

Combines Immetas’ platform for modulating innate immune pathways with GC Biopharma’s mRNA therapeutic and LNP delivery platforms.

Immetas Therapeutics and GC Biopharma have entered into a research collaboration to discover and develop novel mRNA therapeutics for the treatment of a broad range of autoimmune diseases. The collaboration combines Immetas’ platform for modulating innate immune pathways with GC Biopharma’s messenger RNA (mRNA) therapeutic and lipid nanoparticle (LNP) delivery platforms. Immetas will be responsible for identifying therapeutic targets, generating, and characterizing payload molecules, defining ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters